相关实验视频

Updated: May 6, 2026

Microglia as a Surrogate Biosensor to Determine Nanoparticle Neurotoxicity

Microglia as a Surrogate Biosensor to Determine Nanoparticle Neurotoxicity

Published on: October 25, 2016

在阿尔茨海默氏病中,微质细胞利用糖分

Kaitlyn M Marino¹, Daniel C Shippy², Tyler K Ulland³

¹Neuroscience Training Program, University of Wisconsin, 1111 Highland Ave, Madison, WI 53705, United States of America; Department of Pathology and Laboratory Medicine, University of Wisconsin, 1111 Highland Ave, Madison, WI 53705, United States of America.

Journal of neuroimmunology

|February 19, 2025

概括

在阿尔茨海默氏病 (AD) 模型中,饮食中的糖源会影响微质细胞,即大脑的免疫细胞. 微细胞显示基因表达和反应性发生变化,这取决于他们是否摄入葡萄糖或果糖.

科学领域:

神经科学是一个神经科学.
免疫学免疫学免疫学
代谢障碍代谢障碍代谢障碍

背景情况:

糖尿病是阿尔茨海默病 (AD) 发病的一个重要危险因素.
微质,大脑的主要免疫细胞,在AD特征的神经炎症期间表现出代谢变化.
饮食碳水化合物来源对AD相关的微质变化的影响尚不清楚.

研究的目的:

调查不同饮食碳水化合物来源 (葡萄糖与果糖) 对微质基因表达和活性在阿尔茨海默病病理学背景下的影响.
探索糖载体在微质代谢适应不同糖的作用.

主要方法:

对现有的基因表达数据进行分析,以确定糖载体表达的变化 (SLC2A1,SLC2A5).
在体外研究中,使用在葡萄糖或果糖补充介质中培养的N9小鼠微细胞系,并用脂多糖 (LPS) 刺激,随后进行RNA测序.
在体内研究中,使用5XFAD转基因小鼠食含乳糖或果糖的均饮食,随后通过共聚焦显微镜评估粉样蛋白斑块负担和微质反应.

主要成果:

基因表达分析显示了糖载体的差异调节,增加了葡萄糖载体 (Slc2a1) 和减少了果糖载体 (Slc2a5) 的表达.
微质细胞的RNA测序显示,对照基因和糖补充介质之间存在显著的基因表达变化,以及葡萄糖和果糖条件之间的不同配置.
在体内,虽然粉样质斑块负担和整体微质反应在不同饮食中是相似的,但在食用牛糖和果糖的小鼠之间观察到微质反应的显著差异.

结论:

微质优先表达特定的糖载体,表明对可用碳水化合物的量身定制的代谢反应.
饮食糖的来源 (葡萄糖与果糖) 可能会调节微质反应和炎症反应在存在阿尔茨海默病相关的病理.
这些发现突出了饮食成分与阿尔茨海默氏症的神经免疫功能之间的潜在联系,需要进一步调查.

关键词:

阿尔茨海默病的疾病阿尔茨海默病的疾病.果糖是葡萄糖中的一种果糖.葡萄糖是一种葡萄糖.微质细胞中的微质细胞糖的新陈代谢糖的新陈代谢

更多相关视频

Assessing Retinal Microglial Phagocytic Function In Vivo Using a Flow Cytometry-based Assay

Assessing Retinal Microglial Phagocytic Function In Vivo Using a Flow Cytometry-based Assay

Published on: October 18, 2016

In vitro Quantitative Imaging Assay for Phagocytosis of Dead Neuroblastoma Cells by iPSC-Macrophages

In vitro Quantitative Imaging Assay for Phagocytosis of Dead Neuroblastoma Cells by iPSC-Macrophages

Published on: February 14, 2021

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...